Bromocriptine combined with levodopa in Parkinson's disease

Area of Science:

• Neurology
• Pharmacology

Background:

• Parkinson's disease is a progressive neurodegenerative disorder.
• Levodopa combined with a decarboxylase inhibitor is a common treatment for Parkinson's disease.
• Some patients exhibit inadequate response and develop motor complications like dyskinesia and the on-off phenomenon during levodopa therapy.

Purpose of the Study:

• To evaluate the long-term efficacy and safety of bromocriptine in parkinsonian patients with inadequate response to levodopa.
• To assess the impact of bromocriptine on motor symptoms and treatment-related phenomena.

Main Methods:

• A 2-year open-label study involving 17 parkinsonian patients.
• Patients received bromocriptine (Parlodel) in addition to their existing levodopa and decarboxylase inhibitor regimen.
• Dose titration of bromocriptine was performed individually, reaching a mean daily dose of 46 mg.

Main Results:

• Significant improvement (p < 0.001) in bradykinesia, rigidity, tremor, feeding, dressing, and speech after 4 weeks of bromocriptine treatment.
• Sustained improvements observed over the 2-year study period.
• The on-off phenomenon resolved in 9 out of 13 affected patients.
• Mild and transient side effects were reported.
• Pre-existing involuntary movements improved with concomitant reduction in levodopa dosage.

Conclusions:

• Bromocriptine is an effective and well-tolerated adjunctive therapy for Parkinson's disease patients with suboptimal response to levodopa.
• Bromocriptine can significantly improve motor symptoms and mitigate the on-off phenomenon.
• Long-term treatment with bromocriptine demonstrates sustained efficacy and safety in this patient population.